Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen by Jacobsen, Steven J. et al.
A D U ~  UROLOGY 
R 
COMPARABILITY OF THE TANDEM-R AND 
IMx ASSAYS FOR THE MEASUREMENT OF 
SERUM PROSTATE-SPECIFiC ANTIGEN* 
STEVEN J. JACOBSEN, M.D., PH.D. 
HANS LILJA, M.D., PH.D. 
GEORGE G. KLEE, M.D., PH.D. 
GEORGE L. WRIGHT, JR., PH.D. 
KIM PETTERSSON, PH.D. 
JOSEPH E. OESTERLING, M.D. 
From the Department of Health Sciences Research, Section of Clinical Epidemiology, 
and Department of Laboratory Medicine and Pathology, Division of Metabolic and 
Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota; 
Department of Clinical Chemistry, University of Lund, MMmo, Sweden; 
Department of Microbiology and Immunology and Center for Urological Oncology, 
Eastern Virginia Medical School, Norfolk, Virginia; Department of Biotechnology, 
University of Turku, Finland; and The Michigan Prostate Institute, 
University of Michigan, Ann Arbor, Michigan 
ABSTRACT--Objectives. To assess the comparability of the Tandem-R and IMx serum 
prostate-specific antigen (PSA) assays across levels of the ratio of free-to-total serum PSA 
found in a community-based population of healthy men. 
Methods. Banked serum samples from the baseline component of the Olmsted County 
Study of Urinary Symptoms and Health Status Among Men were thawed and analyzed 
using the Tandem-R and IMx PSA assays. Serum levels also were determined for the free, 
noncomplexed form of PSA, PSA complexed to alpha-1 antichymotrypsin, and total PSA 
with a research-based immunofluorometric assay. 
Results. The results of the Tandem-R and IMx assays were strongly correlated at all 
levels of the ratio of free-to-total serum PSA. The Spearman correlation coefficients 
ranged from 0.87 to 0.98 (all p < 0.001). The relationship between the Tandem-R and 
IMx assays, however, differed at low levels of free-to-total serum PSA compared with high 
levels. In the lowest 10th percentile of the ratio of free-to-total serum PSA (0.04 to 0.18}, 
the IMx assay read lower than the Tandem-R (slope _+ standard error = 0.92 +0.04, in- 
tercept _+ standard error = 0.21 _+0.14); whereas in the upper 10th percentile of free-to ~, 
total ratio (0.46 to 0.65) the IMx assay yielded values higher than the Tandem-R assay 
(slope = 1.21 +0.07, intercept = 0.14 +0.05). In the middle 90%, the slope did not sta- 
tistically differ from 1.0. 
Conclusions. For the majority of men, results of the Tandem-R and IMx PSA assays 
were virtually identical. The small differences found would not be of clinical significance 
for most men but should be considered when comparing results of different assays in 
sequential determinations for a specific man. 
Prostate-specific antigen (PSA) is a 33-kDa serine 
protease produced by the epithelium of the prostate 
gland. 1 Serum levels of PSA have been noted to be 
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elevated m men with an enlarged prost~ 
men harboring prostate cancer. 2,5 In in 
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into the systemic circulation are also 
contribute to elevated levels of PSA il 
cancer. 6 The measurement of serum 
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iested that PSA may exist in a 
[pha-2 macroglobulin. 21,22 The 
d PSA complexed to alpha-1 
e both measurable by various 
earch-based assays. The PSA 
la-2 m a c r o g l o b u l i n  is no t  
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itions on samples from a corn- 
of men free of prostate cancer. 
:s were used to determine PSA 
em-R and IMx assays, and the 
al PSA (free and complexed) 
ement of free PSA were deter- 
-~sed immunofluorometric as- 
determinations were used to 
;,ht into the comparability of 
Vlx assays, especially with re- 
ee to complexed PSA. 
L AND METHODS 
of the design and implemen- 
lave been described in detail 
elsewhere. 3,2s-3° The resources of the Rochester Epi- 
demiology Project ~1 were used to identify an age-- 
and residence-stratified random sample of 5135 
men aged 40 to 79 years from the Olmsted County, 
Minnesota population. Men with a documented  
history of prostate cancer, prostatectomy, or speci- 
fied conditions (other than benign prostatic hy- 
perptasia [BPH]) that would  interfere with voiding 
function were excluded from the study (n = 1261). 
The remaining 3874 (75%) were invited to partic- 
ipate in a prospective cohort study of the natural 
history of prostatism. Of those identified, 2115 
(55%) completed a previously validated question- 
naire that assessed urologic and general health. 
From these men, a random sample of 537 (25%) 
was invited to the Mayo Clinic for a detailed clini- 
cal examination that included obtaining a serum 
specimen for PSA determination, digital rectal ex- 
amination, and ultrasonographic examination of 
the prostate. All 3 diagnostic tests were completed 
by 475 men (88%). The results prompted 52 men 
(11%) to undergo an ultrasound-guided biopsy of 
the prostate, and prostate cancer was found in 4 
(8%) of these men. These 4 were excluded from 
subsequent  analyses. 
PSA DETERMINATION5 
Prior to the clinical examination, study subjects 
were phlebotomized at a central clinic facility in the 
morning hours in a nonfasting state. Approximately 
15 mL of venous blood were obtained from each 
subject and divided into 4 aliquots of 3 to 4 mL 
each. Each aliquot was labeled and logged, and all 
but  1 placed in frozen storage at -70°C. The un- 
frozen aliquot was processed immediately in a cen- 
tral laboratory to determine the serum PSA con- 
centration with the Tandem-R PSA assay (Hybritech 
Inc., San Diego, CA). The results of this determi- 
nation have been published previously 3 
In September 1993, I aliquot of serum was with- 
drawn from frozen storage for 395 (84%) of the 471 
men to determine serum PSA levels with several 
assays. The frozen samples were transported on 
dry ice to Turku, Finland, where samples were 
thawed. There the total and free serum PSA con- 
centrations were determined by research-based im- 
munofluorometric  assays. 21,32-34 Total serum PSA 
concent ra t ions  were de te rmined  with a mono-  
cional-monoclonal assay similar to the previously 
described assay. 21 The H117 anti-PSA monoclonal  
ant ibody was used as the capture ant ibody and 
europium-labeled 2H50 anti-PSA as the detection 
antibody. The H l 1 7  and H50 antibodies detect  
different epitopes available on the noncomplexed 
PSA molecule as well as PSA complexed to serine 
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TABLE I. Distribution of serum PSA determinations and differences: 
clinic cohort Qlmsted County study of urinary symptoms 
and health status among men 
Median Q~ Q3 Min Max 
Age (yr) 54 47 64 40 79 
PSA (ng/mL) 
Tandem R 0.9 0.5 1.6 0.1 9.7 
IMx 1.0 0.7 1,7 0.2 11.3 
Difference* 0.13t 0.02 0,26 -2.0 2.4 
Free/total ratio* 0.29 0.23 0.37 0.04 0.65 
KEY: Q¢, 25th percentile; Q3, 75th percentile. 
*Determinotion by IMx - dete77nination by Tandem-R. 
*p <0.001, sign ranl~ test. 
*Ratio of free PSA to total PSA by research-based immunoflaorometric analysis. 
protease inhibitors such as alpha-1 antichymotryp- 
sin. This assay provides an equimolar detection of 
free, noncomplexed PSA and PSA complexed to 
alpha-1 antichymotrypsin. The concentration of 
free PSA was selectively determined with a mono- 
clonal-monoclonal assay similar to the previously 
described assay, 21 except that H1 17 anti-PSA mono- 
clonal antibody was used as the capture antibody 
and 5A10 as the detection antibody. The 5A10 anti- 
body is specific to the free, noncomplexed form of 
PSA. 21 
The remaining serum was refrozen and trans- 
por ted on dry ice to Eastern Virginia Medical  
School, where the serum PSA concentration was 
determined using both the Tandem-R and IMx (Ab- 
bott Laboratories, North Chicago, IL) PSA assays. 35 
The Tandem-R assay is a dual monoclonal immuno- 
radiometric assay. The IMx PSA assay, however, is 
a polyclonal-monoclonat microparticle capture en- 
zyme immunoassay formatted for the IMx system. 
Serum PSA determinations were made according 
to manufac ture r ' s  i n s t ruc t i ons  wi th  s t anda rd  
reagents and methods of quality control. For this re- 
port, analyses are restricted to the more recent de- 
terminations from frozen specimens. 
STATISTICAL. ANALYSES  
The distributions of serum PSA determinations 
by Tandem-R, IMx, and the ratio of free-to-total 
PSA by immunof luoromet r i c  analysis were de- 
scribed in terms of the median and 25th and 75th 
percentile. Systematic differences between the Tan- 
dem-R and IMx assay were tested with the sign 
rank test. Graphic techniqnes were used to exam- 
ine the relationship between the difference between 
the two assays and PSA level and ratio of free-to- 
total PSA and total PSA determined by the IFMA) 6,3r 
The association was quantified with the Spearman 
rank correlation coefficient. Linear least-squares 
regression analyses were performed within strata 
defined by the 10th, 2_ ~ 
percentiles of the distribl 
total PSA. Regression mc 
the IMx result as the de 
dem-R result as the inde 1 
of the slope and intercep 
els were used to describe 
between the two assays. 
assays were in complete 
slope from the regressio 
the intercept would be ,  
confidence interval abot 
excludes the null hypotl 
intercept), the coeffieiel 
from the null value (p <C 
formed using SAS Stati: 
tute, Cary, NC). 
RE5 
The distributions of s 
are presented in Table I. 
sample  of men,  the d 
whether determined by 
strikingly similar. T h e ,  
assays was 0.13 ng/mL, s 
the IMx assay determin; 
than Tandem-R (p <0.1 
the IMx and Tandem-R 
results with the IFMA ( 
ficity for the IMx, Tan 
were 93.8%, 93.8%, ant 
the cntpoint set at 4.0 
ficity decreased with in( 
specific reference ranges 
ficities were 95.6%, 95. c 
free-to-total PSA rangec 
median of 0.29. If the c 
free-to-total ratio was se 
pie would be labeled no: 
labeled abnormal. 
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FIGURE 1. Scatterplot of total 
serum PSA determination by Ton- 
dern-R (x) and IMx (o) by re- 
search-based irnrnunofluorornet- 
ric analysis. Lines represent 
least-squares regression line of 
Tandem-R (dashed line) and IMx 
(solid line) determination by 
IFMA. The correlation, slope, and 
intercept were 0.98, 1.07, and 
-0 .04  for Tandem-R, respec- 
tively; for IMx 0.99, 1.10, and 
0.06, respectively (adapted from 
ref. 30). 
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FIGURE 2 Scatterplot of differ- 
ence in determination of serum 
PSA concentration by IMx and 
Tandern-R assay (IMx minus Tan- 
dem-R) by averaged deterrnina- 
' i r~ :  
I 
:o 
serum PSA determina- terminations by IMx were slightly higher than by 
is plotted against the av- 
as in Figure 2. Although 
above 0, there did not 
upward or downward 
eels (r s = 0.03, p = 0.61). 
".Is, whether  determined 
ed to be higher in sam- 
ee-to-total PSA (Fig. 3) 
of the ratio (rs = -0.49 
th p <0.001). When the 
eterminations was plot- 
:e-to-total PSA (Fig. 4), 
dication of a slight in- 
of the free-to-total ratio, 
Tere slightly lower than 
of free-to-total PSA, de- 
tion. Points above line indicate 
samples in which IMx determi- 
nations were higher than Tan- 
dern-R determinations. Spear- 
man correlation coefficient = 
0.03, p = 0•61. 
Tandem-R (r s = 0.20, p <0.001). 
The stratified regression analyses provide further 
insight into the relationship between Tandern-R 
and IMx assays at different levels of free-to-total 
PSA ratios (Table II). In the groups with cutpoints 
determined by the 10th, 25th, 50th, 75th, and 90th 
percentiles, the estimates of slope in the regression 
of IMx determination on Tandem-R determination 
were significantly different than 1.0 in only the 
upper and lower 10th percentiles. Furthermore,  
the estimates of intercept were significantly differ-- 
ent than 0 in only the higher levels of free-to-total 
ratio• This suggests that for the majority of men the 
difference between lMx and Tandem-R determina- 
tions is fairly constant, with .only a slight upward 
shift in determination by IMx assay. 
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0.20; p < O.i 
TABLE tl. Relationship between Tandem-R and IMx serum PSA assal. 
results, by ratio of free~total PSA: Olmsted County study of  
urinary symptoms and health status among men 
Regression of IMx on Tandem R* 
Slope Intercept 
F/T ratio t n rs* est§ 95% CI II est§ 95% CI 
0 .04-0 .18  43 0.98 0.92 0.86, 1.00 0.21 -0.07,  O. 
0. t 9 - 0 . 2 3  61 0.9-7 1,06 1.00, 1.12 -0 .02  - 0 , 1 7 , 0 .  
0 ,24 -0 .29  88 0.96 ] .06 0.99, 1 . 13 0.08 -0 .02,  O. 
0 .30-0 .37  99 0.97 1.04 0.98, 1.10 0.11 0.01, O. 
0 .38-0 .45  56 0.92 1.02 0.93, 1.11 0.18 0.08, O. 
0 .46-0 .65  37 0.87 1.21 1.08, 1.34 0.14 0.05, O. 
*Least-squares regression analysis of lMx PSA determination on Tandem-R determination, 
*F/T ratio; ratio o]free/tataI serum PSA by immmwfiuorometric analysis, Cutpoints detm~ined by ]Oth, 25th, 50th, 7 
and 90th percentiles. 
~Spearman correlation coefficie~it (all p <O.OOl), 
~Point estimate. 
}[95% confidence irtterval ]or estimate. 
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COMMENT 
tudy provide important in- 
parability of the Tandem-R 
his is timely and important 
]etermination of PSA levels 
tch with different sensitivity 
forms of PSA in the serum. 25 
:he different antibodies used 
?nly at the extremes of free- 
: the difference between the 
ays changes with PSA level. 
)s, the IMx assay reads lower 
;say; and this decrement is 
evets. In contrast, at higher 
IMx assay provides higher 
]em-R assay, and the differ- 
er PSA levels. These differ- 
ue to the different combina- 
d in the various assays, the 
rsus polyclonal antibodies, 
ethodologies, and the rela- 
n the free form of PSA in the 
it must be remembered that 
PSA ratios tend to be found 
1 PSA values. 38 Thus the net 
nation of upward bias in the 
os is counterbalanced by the 
r total serum PSA levels in 
[e, the median PSA level for 
h percentile of free-to-total 
r Tandem-R is 0.51 ng/mL. 
t analyses, the expected IMx 
,,/mL. In the second quartile 
ae median PSA level is 0.92 
ed IMx level would be 1.05 
ces would not be clinically 
e results, several potential 
,t in mind. First, the PSA val- 
ni ty-based sample of men 
:r were concentrated at the 
:urn; there are relatively few 
eterminations at higher lev- 
.ese levels where the impor- 
are being made: whether or 
invasive and minimally in- 
Our results suggest that the 
ays are probably comparable 
)nd potential limitation is in 
the findings. The exclusion 
g the sample, the 55% re- 
usively white composit ion 
lity uncertain. Although the 
<ed samples may not repre- 
'actice, both short-term and 
long-term comparisons of PSA determinations on 
frozen serum samples suggest that PSA is stable 
when handled properly, as in this study# ° 
In summary, these data provide important reas- 
surances about the comparability of the Tandem-R 
and IMx assays for serum PSA levels. For most 
men, they provide nearly identical levels. There are 
situations, however, in which they are not quite so 
close, especially at extremes of the ratios of free-to- 
total serum PSA. This must be kept in mind when 
assessing men thought to have BPH in whom the 
free-to-total ratio may be elevatedJ s In these men, 
the IMx assay may provide slightly higher deter- 
minations than the Tandem-R, which might yield 
slightly more false-positive results for prostate can- 
cer. In men with prostate cancer (in whom the ratio 
may be relatively lower), the IMx may provide de- 
terminations slightly lower than the Tandem-R, po- 
tentially resulting in slightly more false-negative 
results for prostate cancer. Most important, how- 
ever, the small differences should be accounted for 
in sequential determinations made in a given pa- 
tient with the two assays. At this time, however, it 
is not apparent which of these assays may provide 
the most useful, predictive information in the man- 
agement of prostate disease. Further study will be 
required to provide a better understanding of the 
role that determinat ion of serum levels of PSA, 
measured in the free, complexed, or total form can 
play. 
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